Eikon Therapeutics, Inc. EIKN Interest Income (Expense), Operating

Interest Income (Expense), Operating at other companies

First BanCorpFBP

$220.96M+4.0%

PopularBPOP

$670.18M+10.7%

The BancorpTBBK

$88.81M-3.2%

DoubleVerify HoldingsDV

-$273K+8.7%

Morgan StanleyMS

$2.7B+14.9%

Quantum Computing Inc.QUBT

$13.5M+696%

Operating income-$87.3M-22.3%

Net income-$83.0M-21.6%

EPS (diluted)-$2.46+90.9%

Cash & equivalents$161.2M-21.2%

Total debt$254.8M—

Total equity$550.7M+186%

Total assets$850.8M—

Operating cash flow-$89.8M-64.7%

CapEx$262.0K-98.8%

Free cash flow-$90.1M-17.1%

Market cap$521.35M—

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNet.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Eikon Therapeutics, Inc. 's interest income (expense), operating?: Eikon Therapeutics, Inc. (EIKN) reported interest income (expense), operating of $4.38M in Q1 2026.